Loading ...
Sorry, an error occurred while loading the content.

16259FW: NATAP: AASLD Reports

Expand Messages
  • alleypat@comcast.net
    Nov 3, 2006
    • 0 Attachment
      NATAP http://natap.org/
      _______________________________________________

      Reports so far posted

      57th Annual Meeting of the American Association
      for the Study of Liver Diseases
      (AASLD)
      October 27-31, 2006
      Boston, MA
      ��
      ������� Weight-Based Ribavrin Improves SVR Rate for Patients >105 kg (230 lbs) - (11/02/06)
      ��
      ������� Infergen (Consensus Interferon) Phase III DIRECT Study End of Treatment Results - (11/02/06)
      ��
      ������� Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir (VX-950), Pegasys & RBV - (11/02/06)
      ��
      ������� Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
      ��
      ������� Entecavir Resistance 3-Year Update at AASLD - (11/02/06)
      ��
      ������� Entecavir 3-Year Resistance Update - (11/02/06)
      ��
      ������� Entecavir 3-Year Efficacy/Safety Update in HBeAg+ Naives - (11/02/06)
      ��
      ������� Entecavir 3-Year Update on Efficacy & Safety - (11/02/06)
      ��
      ������� Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine - (11/01/06)
      ��
      ������� VX-950 HCV Protease Inhibitor Resistance Profile: combination therapy suppresses drug resistance - (11/01/06)
      ��
      ������� New Drug Lowers AST/ALT Levels in Chronic HCV - (11/01/06)
      ��
      ������� Albuferon Phase 2 Study Results Reported in Posters at AASLD - (11/01/06)
      ��
      ������� Albuferon Quality-Of-Life Reported - (11/01/06)
      ��
      ������� Roche HCV Polymerase Inhibitor Shows Potency: 4 log viral load reduction - (10/31/06)
      ��
      ������� Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment - (10/31/06)
      ��
      ������� SELECTION AND CHARACTERIZATION OF HEPATITIS C VIRUS REPLICONS RESISTANT TO A POTENT POLYMERASE INHIBITOR A-837093 - (10/30/06)
      ��
      ������� In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors - (10/30/06)
      ��
      ������� The Antiviral Efficacy of an HCV Polymerase inhibitor in the Chimpanzee Model: Genotypic and Phenotypic Analysis - (10/30/06)
      ��
      ������� Coffee Appears to Reduce Risk of Fibrosis in HCV+ - (10/30/06)
      ��
      ������� Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold - (10/30/06)
      ��
      ������� Higher Fixed Dosing with PEGASYS in Difficult-to-Treat Patients - (10/30/06)
      ��
      ������� Early Week 4 Response Predicts SVR in Genotype 1 - (10/30/06)
      ��
      ������� Roche's Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients - (10/30/06)
      ��
      ������� Update on NM283, HCV Polymerase Inhibitor, at New 200 mg Dose - (10/30/06)
      ��
      ������� New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting - (10/30/06)
      ��
      ������� Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen (Consensus Interferon) - (10/30/06)
      ��

      [Non-text portions of this message have been removed]